细胞源禽流感病毒三价灭活疫苗(H5N1 Re-11株+Re-12株、H7N9 H7-Re3株)免疫效力研究  

Study on the immune efficacy of cell cell-cultured avian influenza virus(H5+H7)trivalent inactivated vaccine based on Re-11,Re-12,and H7-Re3

作　　者：刘艳晶 潘舒心 麻琦 陈晓涵 邓国华[1] 施建忠[1] 包红梅[1] 田国彬[1] 曾显营[1] 陈化兰[1] LIU Yan-jing;PAN Shu-xin;MA-qi;CHEN Xiao-han;DENG Guo-hua;SHI Jian-zhong;BAO Hong-mei;TIAN Guo-bin;ZENG Xian-ying;CHEN Hua-lan(State Key Lab of Veterinary Biotechnology,Harbin Veterinary Research Institute,Chinese Academy of Agricultural Sciences,Harbin 150069,China)

机构地区：[1]中国农业科学院哈尔滨兽医研究所兽医生物技术国家重点实验室,黑龙江哈尔滨150069

出　　处：《中国预防兽医学报》2022年第3期295-300,共6页Chinese Journal of Preventive Veterinary Medicine

基　　金：国家重点研发计划(2017YFD0500701、2016YFD0501602);现代农业产业技术体系(CARS-41-G12);农村领域国家科技计划课题(2015BAD12B03/001)。

摘　　要：为评估重组禽流感病毒(H5+H7)三价灭活疫苗(细胞源,H5N1 Re-11株+Re-12株、H7N9 H7-Re3株)的免疫效力及对近期分离的H5和H7禽流感病毒(AIV)的免疫保护效果,本研究将3批疫苗以0.3 mL/只接种3周龄SPF鸡,疫苗接种后3周采集血清,检测针对H5亚型Re-11株、Re-12株和H7亚型H7-Re3株AIV的HI抗体效价;免疫后3周,以鼻腔感染的方式分别感染效力检验毒株和近期监测到的H5N1、H5N6和H7亚型AIV,进行攻毒效力试验。结果显示,3批疫苗接种SPF鸡3周时,血清中针对Re-11株、Re-12株和H7-Re3株抗原的平均HI抗体效价均在7.7log2~8.3log2,对照组鸡血清HI抗体均为阴性;分别以100 CLD50攻击H5亚型2.3.4.4h分支、2.3.2.1d分支AIV和H7N9亚型AIV效力检验毒株后14 d内,对照组鸡全部发病死亡且排毒,3批次疫苗免疫组鸡均不发病、不排毒、不死亡,获得完全保护。对近期分离H5和H7亚型AIV的免疫保护效力试验结果显示,接种0.3 mL/只疫苗3周的SPF鸡血清中针对3种抗原的平均HI抗体效价均在8log2左右。分别以105EID50攻击2019年分离的1株H5N6亚型、1株H5N1分离株、2株H7N9亚型AIV及2018年分离的H7N2亚型AIV后14 d内,对照组SPF鸡全部发病死亡,所有免疫组鸡均获得100%免疫保护。以上结果表明,细胞源重组AIV(H5+H7)三价灭活疫苗具有良好的免疫原性,能够完全抵御近期监测到的H7N9亚型AIV及H5N1和H5N6亚型AIV的攻击。本研究为细胞源AIV(H5+H7)三价灭活疫苗(H5N1 Re-11株+Re-12株、H7N9 H7-Re3株)的研发和应用提供了依据。To evaluate the immune efficacy of the cell-cultured recombinant avian influenza(H5+H7)trivalent inactivated vaccine produced by using Re-11,Re-12,and H7-Re3 vaccine seeds and its protection efficacy against the challenge of H5 and H7 strains recently isolated in poultry,groups of 3-week-old SPF chickens were immunized with one dose(0.3 mL)of the vaccine.At 3 weeks post vaccination(p.v.),sera were collected for the detection of the HI antibody titers to H5 subtype Re-11 strain,Re-12 strain and H7 subtype H7-Re3 avian influenza viruses(AIV),respectively,and the vaccine potency test and the challenge study against the H5 N6,H5 N1 and H7 N9 AIVs recently isolated in poultry were performed.In the potency test experiment,one dose(0.3 mL)of vaccine could induce mean HI antibody titers to H5 Re-11 strain,Re-12 strain and H7-Re2 strain ranged from 7.7 log2 to 8.3 log2 in SPF chickens at 3 weeks p.v.,and the relevant HI antibody was negative in control groups.After challenged with 10050%chicken lethal dose of H5 N6 clade 2.3.4.4 h AIV,H5 N1 clade 2.3.2.1 d AIV and H7 N9 AIV,respectively,all the chickens in the control groups died during 14 days observation period,while all immunized chickens survived without clinical sign or virus shedding.In the challenge study against the prevalent strains,the mean HI antibody titers against three antigens reached about 8 log2 in the SPF chickens immunized with one shot(0.3 mL)of the vaccine at 3 weeks p.v..When challenged with one H5 N6 AIV,one H5 N1 AIV,or two H7 N9 antigenic variants isolated in poultry in 2019,as well as one 2018 H7 N2 AIV,all chickens in the control groups died within 6 days post challenge(p.c.),and all immunized chickens were completely protected without any clinical sign or virus shedding.The above results indicated that this cell-cultured vaccine exhibited good immunogenicity in chickens and could completely prevent the challenge of H7 N9 antigenic variants as well as H5 N1 and H5 N6 AIVs recently isolated in poultry.This study provides a test basis for the effe

关 键 词：禽流感 H5+H7 细胞源三价疫苗 鸡 免疫效力 

分 类 号：S852.65[农业科学—基础兽医学]